Clopidogrel response variability has been identified in cats. In humans, evidence suggests that variable clopidogrel active metabolite (CAM) generation is the primary explanation for clopidogrel response variability with differences in body weight, sex, and variable metabolism of clopidogrel primarily due to polymorphisms of the gene encoding cytochrome P450 (CYP) 2C19 as some proposed mechanisms. The aim of this study was to evaluate whether variation in CAM concentrations exists in healthy cats and what the cause of such variation might be. Nineteen healthy cats were given 18.75 mg clopidogrel by mouth. Blood was collected 2 hr later. Plasma CAM concentrations were measured using high performance liquid chromatography and tandem mass spectrometry. Clopidogrel metabolism was estimated by calculating CAM metabolic ratio. DNA was collected, and feline CYP2C genotyping was performed. The cats demonstrated high interindividual variation of plasma CAM concentrations. Approximately 69% of this interindividual variation was primarily explained by differences in clopidogrel metabolism as measured by CAM metabolic ratio with some influence by sex but not by weight. A single nucleotide polymorphism was identified in the feline CYP2C gene that explained in part individual differences in CAM metabolic ratio and CAM plasma concentrations.
| INTRODUC TI ON
Due to improved outcome over aspirin, clopidogrel therapy represents the antiplatelet treatment of choice for the prevention of feline cardiogenic thromboembolism (Hogan et al., 2015) . Clopidogrel is a prodrug. Once absorbed from the gastrointestinal tract, the ma- (KarazniewiczLada et al., 2012; Lyngby, Court, & Lee, 2017; Peer et al., 2012) .
In humans, evidence suggests that variable CAM generation is the primary explanation for clopidogrel response variability. Many mechanisms are thought to cause clopidogrel response variability in people including body weight, sex, and variable metabolism of clopidogrel primarily due to gene polymorphisms affecting the CYP2C subfamily of CYP450 (Backman et al., 2017; Li et al., 2009; Shuldiner et al., 2009; Simon et al., 2009) . Clopidogrel response variability also exists in cats (Hogan et al., 2004; Li, Stern, Ho, Tablin, & Harris, 2016; Teuber & Mischke, 2016) . The cause for variable clopidogrel response in cats is currently unknown. The aim of this study was to evaluate whether variations in CAM concentrations exist in healthy cats given the clinically used dose of 18.75 mg clopidogrel per os and what the cause of such variation might be. We hypothesized that interindividual variability in CAM plasma concentrations would be present and that this variability would be influenced by variability in cat weight, sex, metabolism, and/or CYP2C genetic polymorphisms.
| MATERIAL S AND ME THODS

| Animal inclusion criteria
Eligible client-owned cats were required to be apparently healthy, between 2 and 8 years of age, and >3.4 kg in weight. Written informed owner consent was obtained prior to participation in the study.
Apparent health was determined based on history, a normal physical examination, and normal laboratory values including complete blood count, serum biochemistry panel, urinalysis, negative feline leukemia virus and feline immunodeficiency virus testing, and a normal echocardiogram. All blood work and urinalyses were performed by the Washington State University Clinical Pathology Laboratory.
All echocardiograms were performed by a single investigator (PML).
Conventional 2D, M-mode, and Doppler examinations were performed using an echocardiographic system and transducers ranging from 4 to 10 MHz. This study was approved by the Washington State University Institutional Animal Care and Use Committee.
| Tube preparation
Custom blood collection tubes were prepared by adding 10 μl of 500 mM 2-bromo-3′methoxyacetophenone (BMAP) solution and 20 μl of a 500 mM ethylenediaminetetraacetic acid (EDTA) solution to a 2-ml polypropylene microcentrifuge tube. The 500 mM BMAP solution was created by dissolving 115 mg of BMAP powder into 1 ml of acetonitrile. The 500 mM EDTA solution was created by dissolving 20.2 g of EDTA into 120 ml of water. The EDTA-BMAP blood tubes were stored at 4°C until use within 24 hr.
| Blood and DNA collection
Enrolled cats were administered the standard clinically used dose of 18.75 mg clopidogrel orally. Cats were fasted overnight to minimize variations in gastrointestinal transit times. To ensure dosing accuracy, 75 mg clopidogrel tablets were crushed, quartered based on weight using a gram scale, and placed in a gelatin capsule. Blood was collected 2 hr after clopidogrel administration via jugular venipuncture. Approximately 15 min before blood collection, each cat received 5 mg/kg ketamine, 0.2 mg/kg butorphanol, and 0.2 mg/cat acepromazine intramuscularly in the epaxial muscles. One milliliter of blood was placed into the EDTA-BMAP blood tubes. Once blood was collected, tubes were centrifuged at 2,500 g for 5 min. Plasma was then transferred to cryovials and stored at −80°C until assayed.
Samples for DNA were collected from each cat using cheek swabs, and DNA extracted using a sodium hydroxide precipitation method. and 100 ng/ml, clopidogrel between 0 and 500 ng/ml, and clopidogrel carboxylic acid between 0 and 10 μg/ml. Standard curve samples were prepared to contain 100 μl of blank cat plasma, 100 μl of known amounts of standards, 200 μl of acetonitrile, and 100 μl of the internal standard mixture. 
| Sample preparation for assay by HPLC-MS/MS
| Evaluation of clopidogrel metabolism
CAM-D metabolic ratio was calculated as an indicator of clopidogrel metabolism to CAM. CAM-D metabolic ratio was calculated in order to remove the influence of variable parent drug absorption. To calculate CAM-D metabolic ratio, all concentrations were converted to molarity using the molecular weights of CAM-D 504.4 g/mol, clopidogrel bisulfate 419.9 g/mol, and clopidogrel carboxylic acid 307.8 g/mol. CAM-D molarity was then divided by the sum of clopidogrel molarity and clopidogrel carboxylic acid molarity. This value was then multiplied by 100.
| Feline CYP2C genotyping
At the time of this study, no feline CYP2C gene had been reported in the literature or identified in public DNA databases. Consequently, the feline CYP2C gene, coding region, and associated nonsynonymous SNPs were identified by analysis of publicly available genome sequence data using the following strategy. A text search using the term "CYP2C" was performed on the Felis_catus_8.0 reference genome assembly using the UCSC genome browser in short open reading frames of <220 bp. Consequently, this was considered a pseudogene and was not analyzed further.
Nonsynonymous variants in the feline CYP2C coding region were identified using publicly available whole-genome sequence data for 24 cats with no affiliation to the cats enrolled in this study. Briefly, short sequence reads (study IDs PRJNA288177, were identified in at least two of the 24 cat genomes evaluated.
Information on these variants is provided in 
| RE SULTS
Thirty-five cats were screened for this study, and 19 met the inclusion criteria. Five cats were excluded due to poor temperament, and 11
were excluded due to abnormalities detected during health screening. These abnormalities included elevated alanine aminotransferase (3), inflammatory indicators (3), elevated calcium (1), urinary tract infection (1), heart enlargement on echocardiogram (1), previous diagnosis of blood parasite (1), and abnormality detected on physical examination suggestive of disease (1). One cat was excluded for not meeting the weight requirement. Of the 19 cats, 10 were neutered males, and 9 were spayed females. Eleven were domestic shorthair cats, and 8 were domestic longhair cats. The median age was 3 years TA B L E 1 Location of feline CYP2C coding region SNPs evaluated in this study Genotype frequency data for the four missense SNPs (CYP2C-1, CYP2C-2, CYP2C-3, and CYP2C-4) in the CYP2C gene are shown in Table 6 . Calculated minor allele frequencies were 55%, 39%, 55%, F I G U R E 2 Scatter plot of weight in relationship to derivatized clopidogrel active metabolite (CAM-D) concentration and 3% for CYP2C-1, CYP2C-2, CYP2C-3, and CYP2C-4 (respectively). All SNPs showed genotype frequencies that were consistent with the expected Hardy-Weinberg distribution (p > 0.05). Linkage disequilibrium analysis identified strong inverse linkage between the CYP2C-1 and CYP2C-2 SNPs (r = −0.95; p < 0.001) but no association between the CYP2C-3 and the CYP2C-1 SNPs or between the CYP2C-3 and the CYP2C-2 SNPs (p > 0.05 for both correlations).
TA B L E 3 Weight, derivatized clopidogrel active metabolite (CAM-D) concentration, clopidogrel concentration, clopidogrel carboxylic acid concentration, and CAM-D metabolic ratio for each cat
CYP2C-4 was found in only one cat as a heterozygote so was too infrequent to allow further statistical comparison.
CAM-D concentrations and CAM-D metabolic ratios were
compared between reference, heterozygote, and variant genotype groups by ANOVA (data in Table 6 ). Statistically significant differ- 
| D ISCUSS I ON
This is the first study to demonstrate that high interindividual Body weight, sex, and the rate of drug metabolism are intrinsic physiological factors that can contribute to interindividual variability in the pharmacokinetic disposition of a drug (Martinez, Court, Fink-Gremmels, & Mealey, 2018; Martinez, Gehring, Mochel, Pade, & Pelligand, 2018) . Based on our data, weight does not appear to be a significant cause of variation in CAM-D plasma concentrations in cats. The smallest dosage of clopidogrel given in this study was 1.88 mg/kg and the largest was 5.51 mg/kg representing a 2.9-fold difference in dosages. In comparison, the fold range (highest over lowest) in CAM-D plasma concentrations was 148. This finding supports the currently used per cat dosage of clopidogrel of 18.75 mg/cat rather than using a weight-normalized dosage.
Although weight did not correlate with CAM-D variation, our data showed a significant correlation between CAM-D plasma concentrations and sex when analyzed using both simple and multiple linear regressions (Table 4 ). The effect of sex did not appear to result from differences in clopidogrel metabolism to CAM-D since there was no difference in CAM-D metabolic ratio between male and female cats. However, both CAM-D and clopidogrel carboxylic acid concentrations were significantly higher in the plasma of female cats compared to the plasma of male cats, while no differences in clopidogrel concentrations were appreciated between female and male cats. One possible explanation for this observed sex difference may relate to differences in the fluid and tissue composition between females and males coupled with relative differences in the tissue solubility of CAM-D, clopidogrel carboxylic acid, and clopidogrel. In humans, men have higher total body water, extracellular water, intracellular water, total blood volume, plasma volume, and red blood cell volume than women. Consequently, water-soluble substances will tend to distribute more widely and lead to lower plasma concentrations in men than in women (Soldin & Mattison, 2009) . Clopidogrel is known to be relatively water insoluble while CAM is more water soluble (Remko, Remkova, & Broer, 2016) . Additionally, acids, such as clopidogrel carboxylic acid, tend to be more water soluble. These differences in the solubility of clopidogrel, CAM, and clopidogrel carboxylic acid plus the differences in tissue composition between sexes could explain why CAM and clopidogrel carboxylic acid, but not clopidogrel, plasma concentrations are higher in female cats compared to male cats. Additionally, the lack of correlation between sex and clopidogrel plasma concentrations may have occurred due to the fact that only one plasma sample was collected 2 hr post clopidogrel administration. Because pharmacokinetic parameters will vary between individuals, sampling at 2 hr may reflect C max for certain individuals but not others. This variation has been shown by our group in a previously reported pilot pharmacokinetic study (Lyngby et al., 2017) .
Of the cats in our study, one cat (cat 16: 4-year-old female spayed domestic longhair) showed both a high metabolic ratio and high
CAM-D plasma concentration suggesting that this cat is more likely
to have increased CAM concentrations, excessive response to clopidogrel therapy, and a subsequent higher risk of bleeding. In contrast,
four cats (cat 6: 3-year-old male neutered domestic shorthair, cat 7:
3-year-old male neutered domestic longhair, cat 8: 3-year-old female spayed domestic shorthair, and cat 34: 6-year-old male neutered domestic longhair) showed both a low metabolic ratio and a low CAM-D plasma concentration suggesting that they are likely to have decreased concentrations of CAM, decreased response to clopidogrel, and thus an increased risk of thrombus formation (Figure 3 ).
In people, interindividual differences in metabolism of clopidogrel to CAM are thought to be the primary reason for response variability to clopidogrel (Bonello et al., 2010; Cattaneo, 2010 Niwa & Yamazaki, 2012) , and genetic variants in CYP2C have been widely studied (Hirota, Eguchi, & Ieiri, 2013) . Both loss of function and gain of function mutations in the human CYP2C19 gene have been identified, which can lead to poor response to clopidogrel and increase risk of cardiovascular ischemic events or over response to clopidogrel and increased risk of major bleeding events, respectively (Harmsze et al., 2012; Hulot et al., 2006; Shuldiner et al., 2009; Sibbing et al., 2010) .
The data from this study suggest that SNPs also exist in the feline CYP2C gene that has the potential to influence clopidogrel TA B L E 6 Results of comparisons of plasma derivatized clopidogrel active metabolite (CAM-D) concentrations (ng/ml) and CAM-D metabolic ratios between CYP2C genotype groups by ANOVA after rank transformation in 19 cats administered clopidogrel and genotyped for four nonsynonymous CYP2C SNPs metabolism to CAM in cats. Furthermore, we suspect that the CYP2C-3 SNP may represent a "gain-of-function" allele when compared to the feline reference genome sequence. Higher CAM concentrations were observed in cats with the CYP2C-3 SNP suggesting that the encoded CYP2C enzyme variant, which has an arginine instead of a histidine at amino acid position 231, is more efficient at forming CAM from clopidogrel. This hypothesis could be tested in the future by examining the effect of this SNP on the function of recombinant feline CYP2C enzyme using a heterologous expression system.
There are several limitations to our study. One limitation is the relatively small sample size (n = 19). Consequently, we were unable to evaluate the effects of the rarer SNPs and possible interactions between SNPs and sex. However, this sample size is larger than is typical for other pilot pharmacokinetic studies that usually use 6-10 animals (Brainard, Kleine, Papich, & Budsberg, 2010; Thames et al., 2017) . A second limitation is the fact that blood was collected at only one time point. Consequently, blood draws may not correlate with C max . Additionally, only a single dose of clopidogrel was given to each cat when clopidogrel is normally given chronically. Thus, the pharmacokinetics of clopidogrel in cats might be varied with multiple doses compared to the data from a single dose. Furthermore, the amount of platelet inhibition occurring in each cat was not measured in this study. Therefore, no correlations can be made between CAM-D plasma concentrations and the degree of platelet inhibition.
In conclusion, the results of this study suggest that interindividual variability of plasma CAM-D concentrations is present in cats.
The majority of this variability is due to differences in metabolism and sex. Differences in metabolism may be influenced by sequence variants in the feline CY2C gene.
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